India, Aug. 7 -- INmune Bio Inc. (INMB) Friday announced narrower net loss for the second quarter ended June 30, 2026, owing to absence of a $16.5 million impairment charge, compared to the prior year. The late-stage biotech company also provided several clinical updates for the quarter.
Inmune's pipeline includes XPro1595 for Alzheimer's disease and treatment-resistant depression, INKmune for cancer, and CORDStrom for recessive dystrophic epidermolysis bullosa (RDEB).
Second Quarter Highlights
For the second quarter, loss narrowed by 95% to $1.27 million from $24.46 million in the prior year.
On a per share basis, loss narrowed to $0.05 from $1.05 in the corresponding quarter.
The prior-year period included an impairment charge relate...